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ABSTRACT
During vascular inflammation, the leukocyte-derived enzyme myeloperoxidase (MPO) is
transcytosed across the endothelium and into the sub-endothelial extracellular matrix, where it
promotes endothelial dysfunction by catalytically consuming nitric oxide (NO) produced by
endothelial NO synthase (eNOS). In the presence of chloride ions and hydrogen peroxide (H2O2),
MPO forms the oxidant hypochlorous acid (HOCl). Here we examined the short-term implications
of HOCl produced by endothelial-transcytosed MPO for eNOS activity. Incubation of MPO with
cultured aortic endothelial cells (ECs) resulted in its transport into the sub-endothelium. Exposure
of MPO-containing ECs to low micromolar concentrations of H2O2 yielded enhanced rates of H2O2
consumption that correlated with HOCl formation and increased eNOS enzyme activity. The MPO-
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dependent activation of eNOS occurred despite reduced cellular uptake of the eNOS substrate L-
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arginine, which involved a decrease in the maximal activity (Vmax), but not substrate affinity (Km),
of the major endothelial L-arginine transporter, cationic amino acid transporter-1. Activation of
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eNOS in MPO-containing ECs exposed to H2O2 involved a rapid elevation in cytosolic calcium and
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increased eNOS phosphorylation at Ser-1179 and de-phosphorylation at Thr-497. These signaling
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events were attenuated by intracellular calcium chelation, removal of extracellular calcium and
inhibition of phospholipase C. This study shows that stimulation of endothelial-transcytosed MPO

na

activates eNOS by promoting phospholipase C-dependent calcium signaling and altered eNOS
phosphorylation at Ser-1179 and Thr-497. This may constitute a compensatory signaling response

Jo

oxidative stress.

ur

of ECs aimed at maintaining eNOS activity and NO production in the face of MPO-catalyzed

Key Words: Endothelial dysfunction; endothelial nitric oxide synthase; hydrogen peroxide;
hypochlorous acid; L-arginine; myeloperoxidase; nitric oxide; oxidative stress; reactive oxygen
species; redox signaling.

Abbreviations:

BAPTA-AM,

1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic

acid,

(acetoxymethyl)ester; CAT1, cationic amino acid transporter-1; ECs, endothelial cells; eNOS,
endothelial nitric oxide synthase; H2O2, hydrogen peroxide; HOCl, hypochlorous acid; L-Arg, Larginine; MPO, myeloperoxidase; NO, nitric oxide; O2●−, superoxide anion radical; PLC,
phospholipase C; PSS, physiological salt solution.
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Endothelial-transcytosed MPO generates HOCl in the sub-endothelium
MPO-derived HOCl activates eNOS despite impairing endothelial L-arginine uptake
Activation involves PLC/Ca2+-induced changes in eNOS Ser1179/Thr497 phosphorylation
This pathway preserves eNOS activity in the face of MPO-mediated oxidative stress
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INTRODUCTION
The vascular endothelium plays an essential role in maintaining cardiovascular homeostasis. Key to
this process is the synthesis of nitric oxide (NO) by the endothelial isoform of NO synthase (eNOS)
[1, 2]. In addition to its role in regulating arterial pressure and vascular tone, eNOS-derived NO
retards endothelial-leukocyte interactions, platelet activation and smooth muscle cell proliferation,
thereby exhibiting anti-inflammatory and anti-atherogenic actions [2]. In endothelial cells (ECs),
eNOS is a homodimer comprised of a C-terminal reductase domain linked by a calmodulin-binding
site to an N-terminal oxygenase domain [2, 3]. Enzyme activation requires the flavin-mediated
transport of NADPH-derived electrons through the reductase domain to the N-terminal active-site
heme that catalyzes incorporation of molecular oxygen into the substrate L-arginine (L-Arg),
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generating L-citrulline and NO [2-5]. The activity of eNOS is controlled through various post-
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translational mechanisms. For example, enzyme activity is dependent on the rate of intracellular L-
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Arg transport, principally controlled by the cationic amino acid transporter-1 (CAT1) that resides in
the plasma membrane in close proximity to eNOS [6]. Enzyme activation also occurs in response to
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rapid increases in intracellular calcium that promotes binding of the calcium-calmodulin complex
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and disengagement of an auto-inhibitory loop, thereby accelerating enzyme electron flow [7, 8].
Post-translational eNOS control also involves numerous regulatory protein-protein interactions and

na

temporal changes to the phosphorylation status of particular amino acid residues [4, 9]. Activation
of eNOS in response to a variety of stimuli commonly involves a coordinated increase in

ur

phosphorylation at Ser-1177 (human sequence) or Ser-1179 (bovine sequence) and de-

Jo

phosphorylation at Thr-495 (human sequence) or Thr-497 (bovine sequence) [10-14].
Inflammatory vascular disorders including atherosclerosis, diabetes and hypertension are
characterized by endothelial dysfunction that manifests as an impaired bioactivity of NO [2], with
the extent of impairment an independent predictor of future clinical cardiovascular events [15-18].
Convincing evidence points to oxidative stress as an underlying cause and significant interest
surrounds understanding the oxidative mechanisms at play [2, 19, 20]. Diseased blood vessels
produce elevated levels of reactive oxygen species including the superoxide anion radical (O2●−)
and hydrogen peroxide (H2O2). The rapid reaction of O2●− with NO to form peroxynitrite is a
significant mechanism by which oxidative stress impairs NO bioactivity to cause endothelial
dysfunction [2, 20]. H2O2 also has important implications for NO bioactivity through its ability to
stimulate redox signaling pathways that modulate eNOS activity, in part, by increasing
phosphorylation of the enzyme at Ser-1177/Ser-1179 and de-phosphorylation at Thr-495/Thr-497
[21, 22]. H2O2 also influences endothelial dysfunction by promoting oxidative reactions that can
compromise NO bioactivity including elevating endothelial levels of O2●− and labile iron [23] or
4

through its role as a co-substrate for the oxidant-generating heme enzyme myeloperoxidase (MPO)
[24].
MPO is primarily expressed in circulating neutrophils and monocytes, and in sub-sets of tissue
macrophages [24]. Upon leukocyte activation, MPO is secreted into the phagolysosome and
extracellular milieu where it uses H2O2 and chloride ions to catalyze the formation of hypochlorous
acid (HOCl), a potent oxidant that plays a physiological role in the innate immune host defence
[25]. However, a growing body of clinical and experimental evidence indicates that MPO mediates
oxidative mechanisms modulating vascular NO signaling during cardiovascular disorders. For
example, Vita and colleagues reported that elevated levels of circulating MPO correlated with the
extent of impairment of endothelial function in coronary artery disease patients and Rudolph et al.,
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demonstrated that MPO gene-deficiency protected healthy subjects from endothelial dysfunction

ro

induced by the intravascular administration of nicotine [26, 27]. In animal models of vascular
inflammation or atherosclerosis, MPO inhibitor drugs or MPO gene-deficiency protect against

-p

impairment of NO bioactivity and resultant endothelial dysfunction [28-30].
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Key to MPO promoting endothelial dysfunction is its binding to the luminal surface of the

lP

arterial endothelium and subsequent transcytosis and accumulation in the sub-endothelial
extracellular matrix [28, 31-35]. At this site, MPO is positioned to catalyze focal oxidative reactions

na

capable of altering endothelial function. Accordingly, MPO and evidence of oxidative tissue
damage mediated by MPO-derived oxidants, including HOCl, is detected within the endothelium

ur

and sub-endothelium of diseased human arteries [32, 33, 36-39]. Eiserich et al. reported that
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exposure of endothelial-transcytosed MPO to H2O2 promoted the oxidative consumption of NO via
the enzyme’s NO oxidase function, causing impaired NO bioactivity and endothelial dysfunction
[28]. Sub-endothelial MPO also uses H2O2 to generate HOCl within the sub-endothelium [34].
Here, we investigated the implications of endothelial-transcytosed MPO for eNOS activity and the
signaling events involved.

MATERIALS & METHODS
Cell culture and treatment protocols− Bovine aortic ECs (Lonza) were cultured in flasks coated
with gelatin (Sigma; 0.1% (w/v) in phosphate buffer saline [PBS]) in EBM-2 medium plus
supplements as outlined by the manufacturer (Lonza). Confluent cells between passages 3-9 were
used for experiments. For experiments, ECs were incubated in physiologic salt solution (PSS) (119
mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.15 mM Na2HPO4, 0.4 mM KH2PO4, 5 mM NaHCO3, 5.6
mM glucose, 1.5 mM CaCl2, 22 mM HEPES, pH 7.4). For MPO loading, ECs in PSS containing
5

0.2% bovine serum albumin (BSA) were incubated with purified human neutrophil MPO (20 nM;
Merck Millipore) for up to 2 h, then washed twice in PBS to remove any residual unbound MPO
and incubated in PSS. Control or MPO-containing ECs were then exposed to H2O2 (Merck
Millipore) at increasing concentrations (0-100 µM) and incubated for 0-30 min. In some
experiments, cells were pre-incubated in PSS supplemented with the pharmacological inhibitors
BAPTA-AM or U73122 (Merck Millipore), or incubated in calcium-free PSS prior to H2O2
addition.
Western Blotting− At the end of experiments, PBS-washed ECs were lysed with SDS-loading buffer
(62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 50 mM dithiothreitol and 0.1% bromophenol

of

blue). Lysates were boiled (5 min, 100°C), centrifuged (5 min, 12,000 rpm) and cellular proteins
resolved by SDS-PAGE using 7% Tris-Acetate NuPAGE gels (Invitrogen). Resolved proteins were

ro

transferred onto nitrocellulose membranes using the iBlot Gel Transfer System (Invitrogen).
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Membranes were blocked with 5% non-fat milk in Tris-buffered saline (TBS)-Tween buffer (20
mM Tris, 137 mM NaCl, pH 7.6 and 0.1% Tween) for 30 min and probed with the relevant primary
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antibody (1:1000 dilution) in 5% non-fat dry milk in TBS-Tween buffer overnight at 4°C. Primary

lP

antibodies included mouse monoclonal antibodies against eNOS (BD Biosciences) and HOCloxidized protein (Clone 2D10G9; that does not cross-react with epitopes generated by oxidative
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reactions involving nitrating species, transition metals or lipid peroxidation reactions [40]) or rabbit
polyclonal antibodies against MPO (Merck Millipore), tubulin (Sigma), phospho-eNOS (Ser-
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1177/Ser-1179) (Merck Millipore) and phospho-eNOS (Thr-495/Thr-497) (Merck Millipore). TBS-
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Tween washed membranes were incubated with the relevant anti-mouse or anti-rabbit horseradish
peroxidase-conjugated secondary antibody (1:5000 dilution; Cell Signaling Technology) in 5% nonfat dry milk in TBS-Tween buffer for 1 h at room temperature. Membranes were washed in TBSTween buffer and protein bands detected using ECL Western Blotting detection reagents
(Amersham Biosciences). Densitometric analysis of protein bands was performed using ImageJ
software (National Institute of Health).
Immunocytochemistry− Cells cultured on glass coverslips were fixed with 4% para-formaldehyde
(22 °C, 20 min), free aldehydes quenched with NH4Cl (50 mM) for 5 min and then washed with
PBS. Fixed cells were probed with a rabbit polyclonal antibody against MPO (1:300; Merck
Millipore) or a mouse monoclonal antibody against fibronectin (1:100; Clone E3E, Merck
Millipore), followed by the relevant labelled secondary antibody; i.e., cyanine 2-conjugated goat
anti-mouse (green) or cyanine 3-conjugated donkey anti-rabbit (red) antibodies. Cell nuclei were
stained with DAPI (1:2000). After washing with PBS, cells were mounted in Elvanol (Mowiol 4–
88, Hoechst). Confocal fluorescent images were recorded at room temperature using a 63x oil
6

objective on a Leica TCS SP5 microscope. Reconstructions of confocal images were performed
using Imaris software.
Measurement of H2O2− Cellular metabolism of exogenous H2O2 added to ECs was measured using
the Amplex Red H2O2/peroxidase assay kit (Invitrogen). Briefly, following H2O2 addition to
confluent ECs in PSS, 50 μL aliquots of buffer were collected at the indicated times and transferred
into a 96-well plate containing 50 μL of Amplex Red reaction mix prepared according to the
manufacturer’s instructions. The concentrations of H2O2 were then quantified using a fluorescence
microplate reader with 544 nm excitation and 590 nm emission.
Measurement of cellular L-Arg uptake and eNOS activity− The enzyme activity of eNOS was
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quantified by measuring the conversion of L-[3H]-Arg into L-[3H]-citrulline in ECs as previously
described [21]. Briefly, confluent control or MPO-containing ECs in 6-well plates were exposed to
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10 μM L-Arg and 3.3 μCi L-[3H]-Arg (Perkin Elmer) that was immediately followed by the
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addition of H2O2 and incubation of the cells for a further 10 min. ECs were then washed 3x with
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PBS, lysed with 200 μL of 100% ethanol and then mixed with 2 mL of ice-cold stop buffer (20 mM
sodium acetate, pH 5.5, 1 mM L-citrulline, 2 mM EDTA, 2 mM EGTA). The cellular uptake of

lP

[3H]-L-Arg was measured by collecting 20 μL of the lysate followed by liquid scintillation
counting. The remaining lysate was subjected to anion exchange chromatography using Dowex

na

AG50W-X8 resin columns (Bio-Rad) for the determination of L-[3H]-citrulline as previously

ur

described [21]. To study L-Arg uptake kinetics, confluent control or MPO-containing ECs in 12well plates that were non-treated or H2O2-treated for 30 mins were washed and incubated in PSS

Jo

containing 2.5 μCi/mL [3H]-L-Arg (Perkin-Elmer) and varying concentrations of cold L-Arg (0 –
200 μM) for 5 min before washing and measurement of [3H]-L-Arg in EC lysates by liquid
scintillation counting. L-Arg kinetic analyses were performed as previously described [41].
Measurement of cellular calcium− To measure intracellular calcium transients, ECs were grown on
0.1% gelatin-coated 24-well glass-bottom culture plates (MatTek Corporation) until confluency.
After MPO loading, confluent ECs were incubated in PSS containing the calcium-sensitive dye
Fura-2-AM (5 μM; Thermo Fischer Scientific) and Pluronic F-127 (5 mg/mL; Sigma Aldrich) for
30 min. Cells were washed with warm PBS and replaced with fresh PSS, then left in the microscope
chamber (maintained at 37 °C, 5% CO2) for 90 s to equilibrate before the addition of H2O2.
Fluorescent images were taken every 5 s at 510 nm emission with alternating 340 nm and 380 nm
excitation using a Zeiss SD/TIRF microscope (Zeiss Axio Observer, 63x/1.3 Water/Glycerol
objective, and 21 HE FURA filter). Intracellular calcium was determined by the ratiometric analysis
of F340/F380 images of 3-5 individual cells on a pixel-by-pixel basis using ImageJ software.
7

Statistics− All numerical data are expressed as the mean ± SEM of three or more independent
experiments. Western blots shown are representative of three or more independent experiments.
Statistical differences in column graphs were assessed using Student t-test for the comparison of 2
different treatments or one-way ANOVA with the Bonferroni’s post-hoc test for more than 2
treatments. A two-way ANOVA was performed for statistical analysis of 2 different curves or for
grouped treatments. Statistical analyses were performed using Prism 6 software. A p-value <0.05
was considered statistically significant.

RESULTS
Catalytically active MPO accumulates within the sub-endothelial space of confluent arterial ECs−
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Incubation of confluent ECs with purified human neutrophil MPO resulted in a time-dependent

ro

accumulation of the enzyme, as judged by Western blotting (Fig. 1A). Cellular incorporation of
MPO was detected within 5 min and maximal after 2 h (Fig. 1A). Immunofluorescence confocal

-p

microscopy showed that after 2 h incubation, the majority of MPO was located within the
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basolateral or sub-endothelial compartment with some immunoreactivity observed intracellularly

lP

but none apparent at the apical surface (Fig. 1B). Within the basolateral compartment, MPO colocalized with the sub-endothelial matrix protein fibronectin (Fig. 1B & C). MPO metabolizes H2O2

na

to form compound I, which oxidizes Cl− ions to generate HOCl [42]. Endothelial-transcytosed MPO
was active and capable of producing HOCl. Thus, MPO-containing ECs exhibited a >3-fold

ur

enhanced rate of H2O2 consumption relative to control ECs (Fig. 2A). The enhanced H2O2
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consumption in MPO-containing ECs coincided with HOCl production, measured as the increased
formation of high-molecular weight immuno-reactive material detected by a monoclonal antibody
specific for HOCl-oxidized proteins [37, 40, 43] (Fig. 2B).

H2O2 treatment activates eNOS in MPO-containing ECs despite impairing L-Arg uptake− We next
examined the implications of endothelial-transcytosed MPO for eNOS activity in the absence or
presence of H2O2. Addition of 50 µM H2O2 to MPO-containing ECs induced an approximately 2fold increase in eNOS activity compared to control ECs, ECs treated with H2O2 alone or ECs
containing MPO alone (Fig. 3A). The magnitude of the MPO/H2O2-induced increase in eNOS
activity was similar to that obtained by EC-treatment with the calcium ionophore A23187 (Fig. 3A),
which is commonly employed to elicit robust eNOS activation in ECs. Enzyme activity of eNOS
was significantly elevated in MPO-containing ECs exposed to H2O2 despite an approximately 50%
decrease in EC uptake of L-Arg, a change that was not apparent in cells incubated with MPO or
H2O2 alone (Fig. 3B). When EC levels of L-citrulline produced were normalized to the amount of
EC L-Arg uptake, eNOS activation afforded by the exposure of MPO-containing ECs to H2O2 was
8

approximately 3.5-fold greater than that exhibited by control ECs (Fig. 3C). These findings show
that despite inhibiting the intracellular transport of L-Arg, activation of endothelial-transcytosed
MPO, by H2O2 addition, stimulates eNOS activity in ECs.

Sub-endothelial MPO impairs the rate of EC L-Arg transport− As MPO in the presence of H2O2
impaired EC L-Arg uptake, we next analyzed the amino acids transport kinetics. In ECs, CAT1 is
the principal membrane-bound transporter controlling EC L-Arg uptake and eNOS activity [6, 44].
Consistent with this, EC L-Arg uptake was strongly inhibited by L-lysine (Fig. 4A), a competitive
CAT-1 inhibitor [41, 45]. Analysis of the L-Arg transport kinetics showed that the presence of
MPO significantly inhibited the maximal L-Arg transport rate in ECs exposed to H2O2 (Fig. 4B). A

of

corresponding Eadie-Hofstee plot analysis (Fig. 4C & D) showed that in the presence of MPO/H2O2

ro

the Vmax value was significantly reduced by >50% versus ECs treated with H2O2 alone (Fig. 4E).
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No significant change was noted for the affinity of L-Arg for its transporter (Km value) (Fig. 4F).

H2O2 induces rapid eNOS phosphorylation changes in MPO-containing ECs− We and others have
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previously reported that activation of eNOS by H2O2 at concentrations ≥100 µM involved an
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increase in phosphorylation at Ser-1177/Ser-1179 with a concomitant de-phosphorylation of Thr495/Thr-497 [21-23, 46]. We next examined the implications of endothelial-transcytosed MPO for
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eNOS phosphorylation at these two key regulatory amino acid sites. While treatment of ECs with
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50 µM H2O2 alone caused minor changes to the phosphorylation status of eNOS at Ser-1179
(bovine) and Thr-497 (bovine), addition of H2O2 to MPO-containing ECs induced a time-dependent
increase in eNOS phosphorylation at Ser-1179 and de-phosphorylation at Thr-497 (Fig. 5).
Increases in eNOS Ser-1177 phosphorylation or Thr-495 de-phosphorylation in MPO-containing
ECs were rapid and maximal over 2-5 min after H2O2 addition and returned to baseline over 10-30
min (Fig. 5). Significantly increased eNOS Ser-1179 phosphorylation and Thr-495 dephosphorylation was apparent in MPO-containing ECs exposed to 10-50 μM of H2O2 versus ECs
treated with H2O2 alone (Fig. 6). This data shows that sub-endothelial MPO augments the ability of
low micromolar levels of H2O2 to alter eNOS phosphorylation.

Treatment of MPO-containing ECs with H2O2 increases intracellular calcium− Increases in
cytosolic calcium is a key signaling event necessary for maximal eNOS activation by stimulating
the binding of calmodulin to the enzyme [4, 7]. We therefore next measured the implications of
MPO for intracellular calcium transients. In MPO-containing ECs, H2O2 addition rapidly increased
9

cytosolic calcium levels (Fig. 7A-C). In contrast, no detectable changes were evident in ECs treated
with H2O2 alone. Quantification of the peak intracellular calcium response indicated that exposure
of MPO-containing ECs to 50 μM H2O2 promoted an approximately 10-fold increase in
intracellular calcium compared with H2O2 treatment alone (Fig. 7C). The ability of H2O2 to elevate
cytosolic calcium levels in MPO-containing ECs (Fig. 7D) was inhibited by the removal of
extracellular calcium (Fig. 7E). In MPO-containing ECs initially treated with H2O2 in the absence
of extracellular calcium, which evoked a rapid and small transient increase in cytosolic calcium
(Fig. 7E & F), subsequent addition of extracellular calcium generated an immediate and larger
secondary increase in intracellular calcium levels (Fig. 7F). Together, this data indicates that H2O2
treatment of MPO-containing ECs rapidly increases intracellular calcium levels via stimulation of

ro

of

capacitative calcium entry from the extracellular environment [47].

MPO-induced changes to eNOS phosphorylation require phospholipase C (PLC)-dependent

-p

calcium signaling− Induction of eNOS phosphorylation at Ser-1177/Ser-1179 by several stimuli
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depends on calcium signaling [13, 14, 21]. Chelation of intracellular calcium with BAPTA-AM

lP

(Fig. 8A & B) or removal of extracellular calcium (Fig. 8C & D) both inhibited the MPO/H2O2dependent increase in eNOS phosphorylation at Ser-1179. A principal regulator of calcium

na

signaling is PLC, which converts phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5trisphosphate (IP3) that promotes intracellular calcium transients [48]. Treatment of MPO-

ur

containing ECs with the selective PLC inhibitor U73122 abrogated the increase in cytosolic calcium
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induced by H2O2 addition (Fig. 9A & B). PLC inhibition with U73122 also significantly inhibited
the MPO/H2O2-dependent increases in eNOS phosphorylation at Ser-1179 and de-phosphorylation
at Thr-497 (Fig. 9C-E). These results support a role for PLC-dependent calcium signaling in the
H2O2-induced changes in eNOS phosphorylation that occur in MPO-containing ECs.

DISCUSSION
Inflammatory vascular disease is characterized by the accumulation of leukocyte-derived MPO
within the sub-endothelium where it promotes endothelial dysfunction by catalyzing local oxidative
reactions [28, 32-36]. However, the implications of the oxidative reactions catalyzed by subendothelial MPO for EC signaling and function remain largely unexplored. A major finding of this
study is that the addition of H2O2 to confluent aortic ECs containing sub-endothelial MPO elicits
HOCl formation and the rapid stimulation of eNOS enzyme activity, despite inhibiting EC uptake
of the eNOS substrate L-Arg. The MPO-dependent activation of eNOS involved the PLC10

dependent increase in intracellular calcium levels that signaled for the coordinated changes in eNOS
phosphorylation status at Ser-1179 and Thr-497. Together, this study establishes that subendothelial MPO acutely activates eNOS by stimulating PLC-dependent calcium signaling, which
may represent a compensatory redox cell signaling pathway aimed at preserving NO bioactivity in
the face of MPO-catalyzed oxidative stress (Fig. 10).
To study the implications of sub-endothelial MPO for eNOS we incubated confluent cultures of
arterial ECs with low nanomolar concentrations of purified human MPO and in agreement with
prior work [33, 34], demonstrated that the enzyme is rapidly transported into the basolateral or subendothelial space. The sub-endothelial enzyme deposits remained catalytically active as MPOcontaining ECs more avidly consumed H2O2 concomitant with the generation of HOCl, as indicated

of

by the formation of high molecular weight HOCl-oxidized proteins. Our recent work [34] identified
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that this high molecular weight material recognized by a well-characterized monoclonal antibody
specific for HOCl-oxidized proteins [37, 40, 43] constitutes cross-linked aggregates of sub-
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endothelial matrix proteins, including fibronectin. The present study links the stimulation of HOCl
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generation by sub-endothelial MPO with activation of PLC-dependent calcium signaling and

lP

resultant activation of eNOS.

Activation of eNOS after stimulation of sub-endothelial MPO by H2O2 addition involved a

na

coordinated increase in eNOS phosphorylation at Ser-1179 and de-phosphorylation at Thr-497 in a
H2O2 time- and dose-dependent manner. These coordinated changes in eNOS phosphorylation

ur

promote enzyme electron flow and activation [9] and have been observed for ECs exposed to
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various stimuli including bradykinin, VEGF, shear stress and H2O2 [12-14, 21]. For H2O2 to
promote robust changes in eNOS phosphorylation at these amino acid sites requires exposure of
ECs to concentrations >100 µM, with the changes maximal over 15-45 mins [21, 23]. Here we
demonstrate that in the presence of endothelial-localized MPO, as little as 10 μM H2O2 was
sufficient to rapidly alter eNOS phosphorylation that was maximal at 2-5 mins after oxidant
addition. Therefore, the catalytic conversion of low concentrations of H2O2 into HOCl by
transcytosed-MPO significantly augments the capacity of H2O2 to coordinate changes in eNOS
phosphorylation at Ser-1179 and Thr-497 and stimulate enzyme activity.
Rapid increases in intracellular calcium also contribute to eNOS activation by stimulating the
binding of the calcium-calmodulin complex to the enzyme’s calmodulin-binding domain causing
disruption of an auto-inhibitory loop to facilitate electron transport [7, 8, 49]. In the presence of
transcytosed-MPO, addition of H2O2 rapidly increased intracellular calcium flux that was not
apparent with ECs exposed to H2O2 alone. This rapid MPO-dependent increase in cytosolic calcium
was dependent on PLC activity and the intracellular influx of calcium from the extracellular
medium as it was abrogated by PLC inhibition with U73122 or removal of calcium from the
11

medium. In the absence of extracellular calcium, a small and transient increase in cytosolic calcium
was apparent in MPO-containing ECs upon H2O2 addition, which likely constitutes the PLCdependent transient release of calcium from internal endoplasmic reticulum stores. Notably, readdition of calcium to the extracellular medium generated a larger sustained elevation in
intracellular calcium. Together, these findings are consistent with MPO-dependent activation of
capacitative calcium entry that involves an initial PLC-dependent release of calcium from
endoplasmic reticulum stores, which triggers the subsequent influx of extracellular calcium across
the plasma membrane into the cytosol [47]. Earlier reports demonstrated that exposure of ECs to
H2O2 increased intracellular calcium levels by activating PLC-dependent signaling and the resultant
influx of extracellular calcium [50-52]. This study therefore supports that the conversion of H2O2

of

into HOCl by endothelial-transcytosed MPO significantly augments PLC-dependent capacitative

ro

calcium signaling responses induced by addition of H2O2. The detailed molecular mechanisms by
which endothelial-transcytosed MPO triggers endothelial calcium signaling requires more detailed
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investigations.
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Our findings that HOCl produced by endothelial-transcytosed MPO promotes PLC-dependent

lP

elevation in intracellular calcium and acute activation of eNOS differs from prior studies reporting
that exogenous exposure of ECs to reagent HOCl increases intracellular calcium levels independent

na

of extracellular calcium by oxidatively inactivating the sarco/endoplasmic reticulum Ca2+-ATPase
activity [53] or promotes eNOS uncoupling by oxidizing a zinc-thiolate cluster in the enzyme [54,

ur

55]. Reasons for these differences are unknown but may reflect differences in the cellular sites with

Jo

which HOCl reacts; i.e., due to its high reactivity [56] HOCl added exogenously as a bolus of
reagent oxidant would be expected to principally react at the apical plasma membrane surface of
ECs. In contrast, HOCl produced by endothelial-transcytosed MPO reacts primarily within the subendothelial matrix where MPO accumulates [34].
Endothelial calcium signaling is reported to serve as an upstream signal for the phosphorylation
of eNOS at Ser-1177/Ser-1179 in response to several stimuli including bradykinin, VEGF,
polyphenols and H2O2 [12, 13, 21, 23, 57, 58]. Our data show that PLC-dependent calcium
signaling is important for the H2O2/MPO-dependent increase in eNOS Ser-1179 phosphorylation as
chelation of intracellular calcium with BAPTA-AM, incubation of ECs in the absence of
extracellular calcium or PLC inhibition with U73122, all inhibited eNOS Ser-1179 phosphorylation.
An involvement of PLC-dependent calcium signaling was also apparent for the MPO-dependent dephosphorylation of eNOS at Thr-497 as U73122 also significantly inhibited the decreased Thr-497
phosphorylation in MPO-containing ECs exposed to H2O2. Interestingly, PLC inhibition with
U73122 also elevated basal eNOS phosphorylation at Thr-497, findings consistent with a prior
12

report of an involvement of the calcium-dependent phosphatase calcineurin in the dephosphorylation of eNOS at this amino acid under basal conditions in bovine aortic ECs [12].
While our data identify PLC-dependent calcium signaling as an upstream event necessary for
the MPO-mediated changes in eNOS phosphorylation status, the identity of the PLC isoforms
involved remain unknown. The phosphoinositide-specific PLC enzyme family consists of 13
isoforms that are categorized into 6 families; i.e., β, γ, δ, ε, ζ and η [59, 60]. Depending on the
vascular bed, ECs express 8 or more PLC isoforms [61, 62] and further studies are required to
identify the respective PLC isoform(s) involved in MPO-dependent signaling in ECs. Similarly, the
downstream protein kinase(s) or phosphatase(s) responsible for the MPO-induced changes in eNOS
phosphorylation at Ser-1179 and Thr-497 are unknown. Our prior work showed that exposure of

of

ECs to H2O2 at concentrations >100 µM alone increased eNOS phosphorylation at Ser-1177 and de-

ro

phosphorylation at Thr-495 in a PI3K- and calcium-dependent manner, with the phosphorylation at
Ser-1177 mediated by Akt [21]. However, our preliminary studies testing selective inhibitors of the
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PI3K/Akt pathway and other putative kinases (AMPK, CaMKII, PKC) or phosphatases (PP1, PP2A

re

or calcineurin) [4] do not support their role in the MPO-induced changes in eNOS phosphorylation

lP

status at Ser-1179 or Thr-497. This indicates that the redox signaling pathways responsible for
eNOS activation by sub-endothelial MPO differs from those elicited by H2O2 alone. As such, more

na

detailed studies are necessary to identify the kinases and phosphatases primarily responsible for the
MPO-dependent changes in eNOS phosphorylation.

ur

While our data show that oxidative reactions catalyzed by transcytosed MPO promote redox cell

Jo

signaling events that modulate eNOS activity it is also plausible that MPO could impact on eNOS in
other ways. For example, albumin-bound MPO is transcytosed via caveolae-mediated endocytosis
[63], an active transport mechanism shown to acutely control eNOS activity [64]. Therefore, it is
plausible that the process of MPO transcytosis itself may modulate eNOS activity in real-time. As
endothelial cavolin-1/caveolae levels are reduced during vascular inflammation [65], it is possible
that this also alters MPO transcytosis and its implications for eNOS and NO bioactivity.
A significant finding was that exposure of MPO-containing ECs to low micromolar
concentrations of H2O2 elevated eNOS activity despite a significant reduction in endothelial L-Arg
uptake. Our kinetic analysis support that HOCl produced by endothelial-transcytosed MPO directly
impairs L-Arg uptake principally by reducing the rate of CAT1-mediated transport (Vmax), but not
the affinity of L-Arg (Km) for CAT1. This finding is similar to Venardos et al. reporting that
peroxynitrite attenuated endothelial L-Arg uptake by reducing the Vmax, but not the Km, of the
CAT1 transporter [41]. The molecular and oxidative mechanisms by which MPO-derived HOCl
(the current study) or peroxynitrite [41] inhibits CAT1 warrant further investigations.
13

Impairment of CAT1-mediated L-Arg transport contributes to endothelial dysfunction during
cardiovascular disease [66-68]. Our data therefore support the concept that the generation of HOCl
and inhibition of CAT-1-mediated L-Arg transport represents another mechanism by which subendothelial MPO can mediate endothelial dysfunction. Prior studies have linked MPO to the
impairment of L-Arg bioavailability in other ways. For example, Zhang et al. showed that HOCl
chlorinates L-Arg to form competitive eNOS inhibitors [69]. In further work, von Leitner and
colleagues reported that MPO-derived HOCl also inhibits the activity of dimethylarginine
dimethylaminohydrolase (DDAH-1) causing a build-up of asymmetric dimethylarginine (ADMA)
[70], a competitive substrate with L-Arg for binding to CAT-1 and endogenous inhibitor of NOS
enzymes [71, 72]. Together with the results presented here it is clear that MPO-derived HOCl can

of

adversely impact on L-Arg bioavailability, and hence eNOS activity, through its actions on L-Arg

ro

uptake, L-Arg oxidation and inhibition of DDAH-1.

Collectively, we demonstrate for the first time that despite impairing EC L-Arg uptake,

-p

activation of endothelial-transcytosed MPO acutely stimulates eNOS activity by signaling for PLC-

re

dependent increases in intracellular calcium and the resultant reciprocal changes in the

lP

phosphorylation status of eNOS at Ser-1179 and Thr-497. We envisage that this redox signaling
pathway represents an initial compensatory response of the endothelium to bolster or preserve NO

na

production in the face of MPO-catalyzed oxidative stress. This protective response is likely,
however, to be futile if MPO continues to catalyze oxidative reactions for prolonged periods within

ur

the sub-endothelium, including MPO’s NO oxidase function that can directly scavenge endothelial-

Jo

derived NO [28, 73] and the ongoing formation of HOCl, which can inhibit EC L-Arg uptake, and
at higher concentrations, promote endothelial dysfunction by inducing eNOS uncoupling [54, 55] or
oxidizing soluble guanylate cyclase [30].
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FIGURE LEGENDS

Figure 1. MPO is taken up by ECs in a time-dependent manner and accumulates within the
sub-endothelium. (A) Confluent ECs were incubated with MPO (20 nM) for the indicated times
(0-120 min) and cellular levels of eNOS and MPO assessed in cell lysates by Western Blotting. (B,
C) Confluent ECs on coverslips were incubated with MPO (20 nM) for 2 h, washed and then fixed
with paraformaldehyde and immunostained for MPO (red) or fibronectin (green) by laser confocal
fluorescence microscopy. Serial images were taken along the z-plane using the z-stack feature
included in the microscopy software. Images were processed using ImageJ, where the apical,
intracellular and basolateral planes were determined by referencing the DAPI-stained cell nuclei
(blue).

Figure 2. Endothelial-transcytosed MPO enhances H2O2 metabolism and HOCl production.
(A) ECs were incubated in the absence (Control) or presence of MPO (20 nM) for 2 h, washed and
then exposed to H2O2 (50 µM). At the indicated times, H2O2 concentration in supernatants was
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quantified by the Amplex Red assay. Data represent the mean ± SEM of n=4 independent
experiments; ****p<0.0001 comparing curves using a two-way ANOVA. (B) MPO-containing ECs
were non-treated or treated with H2O2 (50 or 100 µM) for 30 min. Cell lysates were analyzed for
HOCl-oxidized protein or tubulin by Western Blotting, using a monoclonal antibody specific for
HOCl-oxidized proteins (clone 2D10G9) or an anti-tubulin antibody, respectively.

Figure 3. H2O2 activates eNOS in MPO-containing ECs, despite impairing L-Arg uptake. ECs
were incubated in the absence (control, CTL) or presence of MPO (20 nM) for 2 h, washed and then
non-treated or treated with H2O2 (50 µM) for 10 min in buffer containing 10 µM L-Arg and 3.3
µCi/mL [3H]-L-Arg. ECs were also stimulated with A23187 (1 µM) for 10 min. (A) eNOS catalytic
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activity was indexed as the conversion of [3H]-L-Arg into [3H]-L-Citrulline by ECs and expressed

ro

as % control values. (B) L-Arg uptake was indexed as the total radiolabel in EC lysates and
expressed as % control. (C) EC L-Citrulline levels in (A) were normalized to the corresponding L-

-p

Arg uptake levels in (B) and expressed as % control. Data are the mean ± SEM, n=3 independent

re

experiments; *p<0.05, **p<0.01 vs. MPO/H2O2 (one-way ANOVA with Bonferroni’s post-hoc

lP

test), ns (non-significant).
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Figure 4. MPO impairs the rate of EC L-Arg transport. (A) ECs were incubated in the absence
(control, CTL) or presence of L-lysine (Lysine, 1 mM) prior to addition of a cocktail of 10 μM L-

ur

Arg and 2.5 μCi/mL [3H]-L-Arg and incubation for the indicated times. ECs were washed,
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harvested and the levels of intracellular [3H]-L-Arg quantified. Data are the mean DPM ± SEM,
n=3, *p<0.05 comparing curves with a two-way ANOVA. (B-F) ECs were incubated in the absence
or presence of MPO (20 nM) for 2 h, washed and then treated with H2O2 (50 μM) for 30 min. ECs
were then washed and incubated in buffer containing 2.5 μCi/mL [3H]-L-Arg (or 50 nM) and
varying concentrations of cold L-Arg (0-200 μM) for 5 min. (C & D) Eadie-Hofstee plots were
generated using linear regression transformation. (E & F) Vmax and Km were determined using the
Michaelis-Menten equation. Data are the mean ± SEM, n=3, **p<0.01 comparing curves using a
two-way ANOVA or (B) comparing columns using a student t-test (E & F).

Figure 5. H2O2 induces time-dependent changes in eNOS phosphorylation in MPO-containing
ECs. ECs were incubated in the absence or presence of MPO (20 nM) for 2 h, washed and treated
with H2O2 (50 μM) for the indicated times. Cell lysates were analyzed for eNOS phosphorylation
status at Ser-1179 or Thr-497 and total eNOS by Western Blotting. Note: the immunoblots for peNOS (Ser-1179) and p-eNOS (Thr-497) are derived from the same gel and nitrocellulose
membrane, initially probed for p-eNOS (Ser-1179), stripped, and then re-probed for p-eNOS (Thr20

497). The eNOS blot shown represents the identical test samples run at the same time on a separate
gel and nitrocellulose membrane, which was probed for total eNOS. The band intensities of eNOS
phosphorylation at (B) Ser-1179 and (C) Thr-497 were quantified by densitometry using ImageJ
and expressed as a % of untreated control ECs or ECs containing MPO alone. Data are mean ±
SEM, n=3 independent experiments; ***p<0.001, ****p<0.0001 comparing curves using a twoway ANOVA.

Figure 6. H2O2 dose-dependently alters eNOS phosphorylation in MPO-containing ECs. (A)
ECs were incubated in the absence or presence of MPO (20 nM) for 2 h, washed and then exposed
to varying H2O2 concentrations (0-50 μM) for 5 min. Cell lysates were analyzed for eNOS

of

phosphorylation status at Ser-1179 and Thr-497 or total eNOS by Western Blotting. Note: the

ro

immunoblots for p-eNOS (Thr-497) and eNOS are from the same gel and nitrocellulose membrane,
initially probed for p-eNOS Thr-497, stripped, and probed for total eNOS. The p-eNOS (Ser-1179)
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blot shown represents the identical test samples run at the same time on a separate gel and

re

nitrocellulose membrane, which was probed for p-eNOS (Ser-1179). The band intensities of eNOS

lP

phosphorylation at (B) Ser-1179 or (C) Thr-497 were quantified by densitometry using ImageJ and
expressed as a % of untreated control ECs or ECs containing MPO alone. Data are the mean ± SEM

na

from immunoblots of n=3 independent experiments, *p<0.05, ****p<0.0001 by two-way ANOVA.

ur

Figure 7. Treatment of MPO-containing ECs with H2O2 increases intracellular calcium
transients. Confluent ECs were incubated in the absence or presence of MPO (20 nM) for 2 h,
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washed and loaded with Fura2-AM (5 μM) for 30 min. Basal EC calcium levels were initially
recorded for 90 s before addition of H2O2 (50 μM). Fluorescent images were taken every 5 s at 510
nm emission with alternating 340 nm and 380 nm excitation using a Zeiss SD/TIRF microscope.
Intracellular calcium was quantified by the ratio-metric analysis of F340/F380 images. (A)
Fluorescent images of Fura2-loaded control or MPO-containing ECs before (baseline) or after H2O2
treatment (H2O2). (B) Time-dependent change in Fura2 fluorescence in control or MPO-containing
ECs before or after H2O2 treatment, which was added at 1.5 mins. Data is representative of n=4
independent experiments. (C) The peak increase in F340/F380 values above basal levels was
calculated in ECs treated with H2O2 alone (H2O2) and MPO-containing ECs treated with H2O2
(MPO+H2O2). Data are the mean ± SEM, n=4 independent experiments; **p<0.01 Student t-test.
(D-F) Fura-2-loaded MPO-containing ECs incubated in calcium-free buffer were: (D) stimulated
with H2O2 (50 μM) 1 min after the re-addition of calcium (Ca2+, 1.5 mM), (E) treated with H2O2 in
the absence of extracellular calcium, or (F) treated with H2O2 in the absence of extracellular
21

calcium for 3 min before the re-addition of calcium (Ca2+, 1.5 mM) and incubation for a further 2
min. Data shown is representative of n=3 independent experiments.

Figure 8. MPO-induced eNOS phosphorylation at Ser-1179 is calcium-dependent. (A) ECs
were incubated with MPO (20 nM) for 2 h, washed and pre-treated with or without the intracellular
calcium-chelator BAPTA-AM (10 μM) for 30 min. Cells were then treated with H2O2 (50 μM) for
the indicated times. Cell lysates were assessed for eNOS Ser-1179 phosphorylation or total eNOS
by Western Blot. (C) ECs were incubated with MPO (20 nM) for 2 h, washed and replaced with
buffer lacking (-Ca2+) or containing (+Ca2+) 1.5 mM calcium prior to the treatment with H2O2 (50
μM) for 2 or 5 mins. Cell lysates were assessed for eNOS Ser-1177 phosphorylation or total eNOS
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by Western Blot. Note: immunoblots in (A) or (C) of p-eNOS (Ser-1179) and eNOS are from the

ro

same gel and nitrocellulose membrane, initially probed for p-eNOS (Ser-1179), stripped, and reprobed for eNOS. (B & D) The band intensities of eNOS phosphorylation at Ser-1179 were
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quantified by densitometry using ImageJ and expressed as % untreated control ECs. Data are the
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mean ± SEM from n=3 independent experiments; *p<0.05, **p<0.01 using a two-way ANOVA.

Figure 9. PLC inhibition attenuates MPO-dependent calcium signaling and alterations in

na

eNOS phosphorylation. (A, B) ECs were incubated with 20 nM MPO for 2 h, washed and loaded
with 5 μM Fura-2-AM for 30 min. Cells were incubated in the absence (Control, CTL) or presence

ur

of U73122 (2.5 μM) for 5 min prior to addition of 50 μM H2O2 and calcium imaging. Fluorescent
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images were taken every 5 s at 510 nm emission with alternating 340/380 nm excitation.
Intracellular calcium was quantified by the ratio-metric analysis of F340/F380 images. Data in (A)
are representative of n=3 independent experiments and in (B) the mean ± SEM of n=3 independent
experiments; *p<0.05. (C-E) ECs were incubated with 20 nM MPO for 2 h, washed and pre-treated
with or without U73122 (1 μM) for 5 min before H2O2 (50 μM) treatment for the indicated times.
Cell lysates were assessed for eNOS phosphorylation at Ser-1179 or Thr-497 and total eNOS by
Western Blotting. Note the immunoblots for p-eNOS (Ser-1179) and eNOS are from the same gel
and nitrocellulose membrane that was initially probed for p-eNOS (Ser-1179), stripped, and reprobed for total eNOS. The p-eNOS (Thr-497) blot shown is the identical test samples run at the
same time on a separate gel and the nitrocellulose membrane probed for p-eNOS (Thr-497). (D, E)
The band intensities of eNOS phosphorylation at Ser-1179 or Thr-497 were quantified by
densitometry using ImageJ and expressed as % untreated control ECs or ECs containing MPO
alone. Data are the mean ± SEM from immunoblots of n=3 independent experiments; *p<0.05,
**p<0.01, ****p<0.0001 using a two-way ANOVA.
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Figure 10. Implications of endothelial-transcytosed MPO for eNOS. (A) During heightened
vascular inflammation increased circulating levels of leukocyte derived MPO are transcytosed
through endothelial cells and into the sub-endothelial extracellular matrix (ECM). (B) In the
presence of H2O2, endothelial-localized MPO catalyzes the formation of HOCl that (C) impairs the
cellular uptake of the eNOS substrate, L-arginine (L-Arg), via the cationic amino acid transporter-1
(CAT-1). In parallel, MPO-derived HOCl also (D) activates phospholipase C (PLC)-dependent
increases in intracellular calcium, sourced from (E) the extracellular environment. (F) This
increased intracellular calcium activates yet-to-be defined protein kinases/phosphatases that afford
increases in eNOS phosphorylation at Ser-1179 and de-phosphorylation at Thr-497, (G) resulting in
an increase in eNOS activity and NO production. (H) The MPO-dependent increase in NO may,
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however, not translate into increased NO bioactivity as MPO in the presence of H2O2 can

ro

catalytically consume NO via its NO oxidase activity. Note: this summary scheme does not
accurately illustrate the specific sub-cellular locations at which the different oxidative and cell
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signaling events occur, the nature of which require further investigation.
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Endothelial-transcytosed MPO generates HOCl in the sub-endothelium
MPO-derived HOCl activates eNOS despite impairing endothelial L-arginine uptake
Activation involves PLC/Ca2+-induced changes in eNOS Ser1179/Thr497
phosphorylation
This pathway preserves eNOS activity in the face of MPO-mediated oxidative stress
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